What do systematic reviews say?

Fondaparinux vs low molecular weight heparin

Fondaparinux probably leads to lower total DVT compared with LMWH (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.54 [0.4, 0.71]
  10 studies · 9356 participants
  Moderate

Fondaparinux vs variable dose warfarin

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 236 participants
  Very low

Fondaparinux vs 1 mg warfarin

It is very uncertain whether fondaparinux changes total DVT compared with 1 mg warfarin (very low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.12]
  1 study · 236 participants
  Very low

Fondaparinux vs placebo

Fondaparinux probably leads to lower total DVT compared with placebo (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.25 [0.15, 0.4]
  8 studies · 5715 participants
  Moderate

Fondaparinux vs edoxaban

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Fondaparinux vs mechanical thromboprophylaxis

Fondaparinux showed no clear difference in total DVT compared with mechanical thromboprophylaxis (low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.63 [0.23, 1.72]
  1 study · 100 participants
  Low